CAJ | 학술논문

目的：观察甘露聚糖肽序贯联合多西他赛、卡铂化疗方案治疗晚期卵巢癌的临床疗效。方法：选择2005年4月～2011年3月就诊的卵巢癌患者120例，随机分为试验组60例，对照组30例，空白组30例，三组均行多西他赛、卡铂化疗，试验组院内注射甘露聚糖肽注射液，出院口服甘露聚糖肽胶囊；对照组院内注射胸腺肽，出院口服胸腺肽肠溶胶囊；空白组患者住院注射等体积的生理盐水，出院口服安慰剂。结果：试验组总有效率为73.33%，显著高于空白组（P=0.011），但与对照组相比差异无统计学意义（P=0.18）。试验组患者Ⅲ～Ⅳ度毒副反应发生率较对照组和空白组显著降低（P＜0.05），中位生存期、1年生存率、2年生存率及化疗1年生存质量均较对照组和空白组显著提高（P＜0.05）。治疗后试验组患者CD4+、CD8+、CD4+/CD8+，外周WBC、中性粒细胞均较对照组、空白组显著提高（P＜0.05）。结论：甘露聚糖肽联合多西他赛、卡铂治疗晚期卵巢癌，能增强患者机体免疫功能，有效提高化疗临床疗效，降低毒副反应发生率，改善生存质量，延长生存期。
목적：관찰감로취당태서관연합다서타새、잡박화료방안치료만기란소암적림상료효。방법：선택2005년4월～2011년3월취진적란소암환자120례，수궤분위시험조60례，대조조30례，공백조30례，삼조균행다서타새、잡박화료，시험조원내주사감로취당태주사액，출원구복감로취당태효낭；대조조원내주사흉선태，출원구복흉선태장용효낭；공백조환자주원주사등체적적생리염수，출원구복안위제。결과：시험조총유효솔위73.33%，현저고우공백조（P=0.011），단여대조조상비차이무통계학의의（P=0.18）。시험조환자Ⅲ～Ⅳ도독부반응발생솔교대조조화공백조현저강저（P＜0.05），중위생존기、1년생존솔、2년생존솔급화료1년생존질량균교대조조화공백조현저제고（P＜0.05）。치료후시험조환자CD4+、CD8+、CD4+/CD8+，외주WBC、중성립세포균교대조조、공백조현저제고（P＜0.05）。결론：감로취당태연합다서타새、잡박치료만기란소암，능증강환자궤체면역공능，유효제고화료림상료효，강저독부반응발생솔，개선생존질량，연장생존기。
Objective: To observe the clinical effect of sequential Mannatide combined with docetaxel,carboplatin chemotherapy in the treatment of advanced ovarian cancer.Methods:120 patients with advance ovarian cancer were chosen in our hospital during April 2005 to march 2011 to be divided into experimental group(n=60),control group(n=30), blank control group(n=30). all the three groups used docetaxel,carboplatin chemotherapy,while the patients in the experimental group used mannatide injection in hospital and oral manntide capsule out, the control group in hospital took thymopetidum for injection and orally thymopeptide enteric-coated capsules out,the blank group used equal volume saline water in hospital and oral placebo out.Results:He total effective rate was 73.33% in the experimental group, significantly higher than that of the blank group (P=0.011), but had no significant difference with the control group(P=0.18).Ⅲ~Ⅳ adverse reaction rate of the expeimental group decreased significantly (P<0.05) ,compared with the control group and the blank control group, the median survival time, 1 year survival rate, 2 years survival rate and 1 year chemotherapy survival quality were significantly better increased than those of control group and blank group (P<0.05). CD4+,CD8+,CD4+/CD8+,peripheral WBC, neutrophils of the patients in the experimental group after treatment went up significantly (P<0.05).contrasted with the control group and the blank control group.Conclusion:Mannatide combined with docetaxel, carboplatin in the treatment of advanced ovarian cancer can enhance the immune function of patients , heighten clinical curative effect of chemotherapy, reduce the incidence of adverse reactions, improve living quality, prolong the survival period.